P/E ratio for Sangamo Therapeutics (SGMO)

P/E ratio history for Sangamo Therapeutics from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Gilead Sciences GILD	19.1	-3,157.86%	🇺🇸 USA
Alnylam Pharmaceuticals ALNY	-67.2	10,657.38%	🇺🇸 USA
Amgen AMGN	23.7	-3,898.74%	🇺🇸 USA
Biogen BIIB	10.9	-1,845.95%	🇺🇸 USA
Dow DOW	28.7	-4,699.14%	🇺🇸 USA
Johnson & Johnson JNJ	11.7	-1,972.26%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	91.7	-14,773.39%	🇺🇸 USA
Merck MRK	64.4	-10,396.43%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.